Trial Information
Summary: A Randomized,Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia.
This is a randomized, double-blind, placebo-controlled
multicenter study to evaluate if the study drug, tadalafil, will
improve the signs and symptoms of enlarged prostate gland (also
known as benign prostatic hyperplasia or BPH). This study will also
aim to show the safety of tadalafil and to see what dose of
tadalafil (2.5mg, 5mg, 10mg, 20mg) taken once a day will help
improve the symptoms of BPH.
Compensation Provided
Patient Inclusion/Exclusion Criteria:
To be in the study, you should:
- Be at least 45 years or older
- Have had signs and symptoms of BPH for at least 6 months. These
include:frequent & urgent need to urinate, trouble starting or
maintaining a urine stream, urinating a small amount, feeling of
needing to urinate again even after just finished urinating, and
leaking or dribbling of urine.
- Have problems with urine flow.
- Agree not to use any other treatments for BPH, including alpha
blockers or herbal preparations during the study.
- Agree not to use any other oral treatment for erectile
dysfunction (ED), including herbal medications during the
study.
You cannot participate in this study if you:
- Are taking certain medications, called nitrates (nitroglycerin)
for heart disease.
- Have a urinary tract infection, are unable to urinate due to
blockage, or have a large amount of urine remaining in your bladder
after urinating.
- Have a significant kidney problem or liver problem.
- Have chest pain, called unstable angina or angina, requiring
medical treatment.
- Have heart disease where less than ordinary activity causes you
to have symptoms.
- Have history of any of the following coronary conditions in the
past 90 days: heart attack also known as myocardial infarction;
heart bypass surgery called coronary artery bypass graft surgery;
percutaneous coronary intervention such as angioplasty or stent
placement.
- Have uncontrolled high or low blood pressure.
- Have uncontrolled diabetes (&qout;sugar
diabetes&qout;).
- Have had a stroke or a significant injury to the spine.
- Are being treated for cancer.
|
Contact:
Lourdes Campos-Grundvig, RN
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Telephone: (212) 241-3141
Fax: (212) 876-3246
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: July 10, 2008 at 2:50:54 PM